TY - JOUR
T1 - A cluster-randomised controlled trial integrating a community-based water, sanitation and hygiene programme, with mass distribution of albendazole to reduce intestinal parasites in Timor-Leste
T2 - the WASH for WORMS research protocol
AU - Nery, Susana Vaz
AU - McCarthy, James S.
AU - Traub, Rebecca
AU - Andrews, Ross M.
AU - Black, Jim
AU - Gray, Darren
AU - Weking, Edmund
AU - Atkinson, Jo An
AU - Campbell, Suzy
AU - Francis, Naomi
AU - Vallely, Andrew
AU - Williams, Gail
AU - Clements, Archie
N1 - Funding Information:
The authors would like to acknowledge the Ministry of Health of Timor-Leste for the albendazole distributed in the trial; the WASH for WORMS?, WaterAid?s and their partner?s field staff for carrying out work in the field; Darren White for his contribution to improving field procedures, and the communities for participating in the trial. This study is funded by a Partnership for Better Health?Project grant from the Australian National Health and Research Council (NHMRC) (APP1013713). DG holds a NHMRC Career Development Fellowship (APP1090221); AC holds a NHMRC Senior Research Fellowship (APP1058878).
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2015
Y1 - 2015
N2 - Introduction: There is limited evidence demonstrating the benefits of community-based water, sanitation and hygiene (WASH) programmes on infections with soil-transmitted helminths (STH) and intestinal protozoa. Our study aims to contribute to that evidence base by investigating the effectiveness of combining two complementary approaches for control of STH: periodic mass administration of albendazole, and delivery of a community-based WASH programme. Methods and analysis: WASH for WORMS is a cluster-randomised controlled trial to test the hypothesis that a community-based WASH intervention integrated with periodic mass distribution of albendazole will be more effective in reducing infections with STH and protozoa than mass deworming alone. All 18 participating rural communities in Timor-Leste receive mass chemotherapy every 6 months. Half the communities also receive the community-based WASH programme. Primary outcomes are the cumulative incidence of infection with STH. Secondary outcomes include the prevalence of protozoa; intensity of infection with STH; as well as morbidity indicators (anaemia, stunting and wasting). Each of the trial outcomes will be compared between control and intervention communities. End points will be measured 2 years after the first albendazole distribution; and midpoints are measured at 6 months intervals (12 months for haemoglobin and anthropometric indexes). Mixed-methods research will also be conducted in order to identify barriers and enablers associated with the acceptability and uptake of the WASH programme. Ethics and dissemination: Ethics approval was obtained from the human ethics committees at the University of Queensland, Australian National University, Timorese Ministry of Health, and University of Melbourne. The results of the trial will be published in peer-reviewed journals presented at national and international conferences, and disseminated to relevant stakeholders in health and WASH programmes.
AB - Introduction: There is limited evidence demonstrating the benefits of community-based water, sanitation and hygiene (WASH) programmes on infections with soil-transmitted helminths (STH) and intestinal protozoa. Our study aims to contribute to that evidence base by investigating the effectiveness of combining two complementary approaches for control of STH: periodic mass administration of albendazole, and delivery of a community-based WASH programme. Methods and analysis: WASH for WORMS is a cluster-randomised controlled trial to test the hypothesis that a community-based WASH intervention integrated with periodic mass distribution of albendazole will be more effective in reducing infections with STH and protozoa than mass deworming alone. All 18 participating rural communities in Timor-Leste receive mass chemotherapy every 6 months. Half the communities also receive the community-based WASH programme. Primary outcomes are the cumulative incidence of infection with STH. Secondary outcomes include the prevalence of protozoa; intensity of infection with STH; as well as morbidity indicators (anaemia, stunting and wasting). Each of the trial outcomes will be compared between control and intervention communities. End points will be measured 2 years after the first albendazole distribution; and midpoints are measured at 6 months intervals (12 months for haemoglobin and anthropometric indexes). Mixed-methods research will also be conducted in order to identify barriers and enablers associated with the acceptability and uptake of the WASH programme. Ethics and dissemination: Ethics approval was obtained from the human ethics committees at the University of Queensland, Australian National University, Timorese Ministry of Health, and University of Melbourne. The results of the trial will be published in peer-reviewed journals presented at national and international conferences, and disseminated to relevant stakeholders in health and WASH programmes.
UR - http://www.scopus.com/inward/record.url?scp=84956518795&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2015-009293
DO - 10.1136/bmjopen-2015-009293
M3 - Article
C2 - 26719316
AN - SCOPUS:84956518795
VL - 5
JO - BMJ Open
JF - BMJ Open
SN - 2044-6055
IS - 12
M1 - e009293
ER -